The anti-MET monoclonal antibody, onartuzumab, has been studied in a phase III trial of onartuzumab plus mFOLFOX6 vs placebo plus mFOLFOX6 in patients with metastatic HER2-negative G/GEJ cancers. Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. Even though substantial advances have been made in the treatment of GC, further research and development are still necessary. and transmitted securely. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.) 2022;3(11): 100814. Gefitinib and EGFR gene copy number aberrations in esophageal cancer. A recent study reconstructed unreported KaplanMeier plots of PD-L1 CPS subgroups of three phase III trials (CheckMate-649, KEYNOTE-062, and KEYNOTE-590) and investigated the outcome of low CPS subgroup [87]. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update. Natural history of abdominal aortic aneurysm: a survey of 63 patients treated nonoperatively. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. 2022;20(2):16792. Guan WL, et al. Takahari D, et al. xml PDF / EPUB. Cancer Commun (Lond). Trastuzumab deruxtecan (T-DXd) is an antibodydrug conjugate (ADC) composed of an anti-HER2 antibody connected to a cytotoxic topoisomerase I inhibitor via a cleavable tetrapeptide-based linker [130]. Rui-Hua Xu. 2017;18(5):64053. Lancet Oncol. Xu R-H, et al. Most recently, the preliminary data presented at ESMO 2022 illustrated that KN026 plus KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody, had remarkable efficacy and tolerable safety in HER2-positive G/GEJ patients without prior systemic treatment [128]. Molecular targeted therapy remains an essential treatment option for patients with advanced GC, aimed to inhibit tumor proliferation and increase survival rates. 2021;149(6):132231. Provided by the Springer Nature SharedIt content-sharing initiative, Clinical & Experimental Metastasis (2023), Future Journal of Pharmaceutical Sciences (2021), Nature Cancer (Nat Cancer) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. 2022;15(1):111. Objective . The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. Lancet Gastroenterol Hepatol. Hall PS, et al. Open Access Review article. Guide for authors - Cancer Treatment and Research Communications - Elsevier The question of simultaneous operation on the aorta and on the stomach, as well as the choice of endovascular or open vascular prosthetics remains open. Longitudinal change of circulating tumor cell level and its 2023;34(3):31920. While the treatment options available for patients with well-differentiated NETs have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. State-of-the-art management of HER2-negative early breast cancer EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. After the completion, the abdominal cavity was lavaged with antiseptic solutions, which was a prevention of bacterial contamination of the aortic graft and allowed safe operation on the aorta. Google Scholar. The Author(s) 2023. The Reports in Cancer and Treatment is a peer reviewed journal that publishes manuscripts on the recent findings in the field of carcinogenesis, mutagenesis, metastasis, cancer genomics and therapeutic approaches for the treatment of different types of cancer. Tsuji Y, Morimoto N, Tanaka H, Okada K, Matsuda H, Tsukube T, Watanabe Y, Okita Y. Biology (Basel). These findings indicated that RC48 exerted considerable anti-tumor effectiveness and tolerable safety in patients with HER2-positive GC, as well as in those with HER2 low expression GC. Gastric Cancer. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. In compliance with generally accepted rules of aseptic and antiseptics, the risk of infection of the vascular prosthesis is minimized. Google Scholar. Sahin U, et al. 2015;18(3):45866. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. We assessed (1 . Ann Oncol. CAS Ogitani Y, et al. Moehler MH, et al. INTRODUCTION Types of Articles Prior Publication Submission Checklist BEFORE YOU BEGIN Ethics in publishing Studies in humans and animals Informed consent and patient details Declaration of competing interest Declaration of generative AI in scientific writing Submission declaration and verification Use of inclusive language Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;8(6):696713. A drug shortage is forcing doctors to reduce doses of chemotherapy. On the 7th day after the surgery, the patient was discharged home in satisfactory condition. J Clin Oncol. ), the Science and Technology Program of Guangdong (Grant No. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. 2021;39(15):TPS4151. PubMed Bull Cancer. Macroscopicallystomach with tumor (the tumor is indicated by arrows): A stomach with greater and lesser omentum; B the stomach is cut lengthwise. Noh SH, et al. Future Oncol. A case report of metastatic lung adenocarcinoma with : Medicine Li J, et al. 2021;71(3):20949. 2014;32(19):203949. Moehler M, et al. 2023;41(36_suppl):405736405736. Ivan Ivashov. Part of Upadhaya S, et al. Yagi S, et al. Cancer Treatment Reports - ResearchGate Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. National Library of Medicine 2019;30(9):147986. Qin S, et al. PubMed [Skip to Navigation] Our website uses cookies to enhance your experience. The ORR was confirmed to be 37.9%, and the DCR was 55.2%. Cite this article. Wilke H, et al. 2017;8:CD004064. No changes in the large and small intestine were detected. Gut. For permissions, please email: journals.permissions@oup.com, This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (, Bilaterality, not multifocality, is an independent risk factor for recurrence in low risk papillary thyroid cancer, Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia, Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools, Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting, Risk of ER-specific breast cancer by family history of ER subtypes and other cancers, https://academic.oup.com/pages/standard-publication-reuse-rights, Receive exclusive offers and updates from Oxford Academic, MEDICAL MICROBIOLOGY AND CLINICAL LABORATORY MEDICINE PHYSICIAN, CLINICAL CHEMISTRY LABORATORY MEDICINE PHYSICIAN. 2021;20(3):1689. Makiyama A, et al. Mol Cancer Ther. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Sci Rep. 2015;5:9289. Bang YJ, et al. statement and 2011;29(13):171521. Your US state privacy rights, Ann Oncol. SEER*Stat software, version 8.3.9. Arch Surg. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. However, the reliable cut-off value to predict the benefit of immunotherapy is needed to be determined. A copy of the written consent is available for review by the Editor-in-Chief of this journal. In the subgroup analysis of the KEYNOTE-061 study, the TMB status (10 or<10 mut/Mb) was associated with response rate, PFS, and OS in patients treated with pembrolizumab. 2014;15(8):894904. Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 20002016. Berry LL, Davis SW, Godfrey Flynn A, Landercasper J, Deming KA. Aneurysm of the abdominal aorta is the most common type of vascular aneurysm, while in 75% of the cases it is asymptomatic. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Tabernero J, et al. 2012 Jul-Aug;62(4):220-41. doi: 10.3322/caac.21149. HER-family ligands promote acquired resistance to trastuzumab in gastric cancer. N Engl J Med. 2019;22(3):52735. Shitara K, et al. Ann Vasc Dis. JNCI: Journal of the National Cancer Institute, 2023;, djad096, . PubMed Other novel therapeutic approaches are being under investigation, including anti-HER2 CAR-T-cell therapy (NCT04511871, NCT04650451), CAR-natural killer cell (NK) therapy [141], and CAR-macrophage (CAR-M) therapy (NCT04660929), B-cell and monocyte-based immunotherapeutic vaccines (BVAC-B), BAY2701439 and CAM-H2 targeted HER2 radiotherapy (NCT04147819, NCT04467515). J Clin Oncol. 2019;37(15_suppl):40174017. Firstly, it is necessary to explore ways to advance ADCs as first-line therapy to benefit a larger number of patients. J Clin Oncol. Recently, the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 trial reported the results of its first interim analysis [73], in which patients with metastatic HER2-positive GC or GEJ cancer received pembrolizumab or placebo plus trastuzumab and chemotherapy. Additionally, trastuzumab beyond progression also failed to show a survival benefit in pre-treated HER2-positive GC patients in the T-ACT trial [100]. Top 100 in Cancer. Google Scholar. Article GRAIDS provided both real-time and retrospective assistance for enhancing the effectiveness of upper gastrointestinal cancer screening and diagnosis, with high diagnostic accuracy and sensitivity in detecting upper gastrointestinal cancers. Am J Clin Pathol. Cancer Commun (Lond). Accessed 4 Sept 2018. Casak SJ, et al. Rivera F, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. In a separate Review, Frank McCormick and colleagues discuss the multiple and complex links between oncogenic KRASone of the most frequently mutated and, as noted above, hard-to-target cancer driversand metabolism, highlighting the potentially targetable vulnerabilities that arise at the interface of the two5. The site is secure. The aorta was pinched immediately under the renal arteries and 1cm above the bifurcation. These patients did not usually respond to HER2-targeted therapy, but MET and HER2 combination inhibition could sometimes bring extra clinical benefit [111]. 2022;40(16_suppl):40404040. The impact of mismatch repair status on prognosis of patients with gastric cancer: a multicenter analysis. This year's report also discusses the critical issue of health equity in cancer research and solutions to ensure that every patient with cancer . The latest generation of ADCs has expanded the treatment population to include novel targets and demonstrated superior clinical outcomes compared to traditional chemotherapy drugs. Subgroup analysis indicated a correlation between moderate-to-strong CLDN18.2 expression and a better overall survival rate. Oncologist. 2021;6(1): 100036. Doi T, et al. Google Scholar. Lu L, et al. Japanese Gastric Cancer, A.Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). 2020;38(15_suppl):45024502. Unlike T-DM1, disitamab vedotin has a bypass-killing effect on nearby tumor cells regardless of HER2 status, which could help overcome spatial heterogeneity and enhance anti-tumor effects. 1967;95:40212. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Nat Commun. Petty RD, et al. The landmark ToGA trial revealed that trastuzumab plus chemotherapy significantly improved the overall survival of patients with advanced GC [14], especially for patients with HER2 positivity, who were identified as having HER2 immunohistochemistry (IHC) scores of 2+and fluorescence in situ hybridization (FISH)-positive or HER2 IHC 3+based on a post-hoc exploratory analysis [92]. J Clin Oncol. 2014;32(2):35561. Ouyang Y, Zhu Y, Chen H, Li G, Hu X, Luo H, Li Z, Han S. Front Oncol. A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors. Unauthorized use of these marks is strictly prohibited. Despite the many milestones achieved in cancer treatment, much remains to be addressed. 2018;29(4):103748. Fukuoka S, et al. J Clin Oncol. Initial results from FRUTIGA showed that fruquintinib combined with paclitaxel showed significant improvements in PFS, ORR and DCR. 2021;41(11):110015. J Clin Oncol. J Clin Oncol. The Million-Dollar Cancer Treatment: Who Will Pay? - WSJ Seo S, et al. However, this benefit was not seen compared to chemotherapy in the KEYNOTE-061/062 trials [53, 84]. Case presentation We . Therefore, the role of EBV positivity in immunotherapy for GC remains unclear and requires further investigation. These findings highlight the significance of ctDNA as a biomarker for predicting patient outcomes following perioperative cancer treatment and surgical resection in patients with GC. Journal Indexing and Metrics: Technology in Cancer Research & Treatment American Society of Anesthesiologists Physical Status Classification System. Liquid biopsies can detect a broader spectrum of abnormalities in a heterogeneous tumor compared to conventional tissue biopsies. Impact Factor Cancer Discovery: 38.272 Cancer Epidemiology, Biomarkers & Prevention: 4.090 Cancer Immunology Research: 12.020 Cancer Prevention Research: 3.296 Cancer Research: 13.312 Clinical Cancer Research: 13.801 Molecular Cancer Research: 6.333 Molecular Cancer Therapeutics: 6.009 Futibatinib, an irreversible and highly selective FGFR14 inhibitor that permanently disables FGFR2, has been tested in a phase II trial involving patients with advanced-stage solid tumors harboring FGFR alterations, including those with FGFR2-amplified G/GEJ cancers [168]. Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: preliminary results. The trial showed a 2-month improvement in PFS, and the OS was not reached (NR) in the experimental arm (bemarituzumab+mFOLFOX6).